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Glioblastoma is the most frequently diagnosed type of primary brain
tumour in adults. These aggressive tumours are characterised by inherent
treatment resistance and disease progression, contributing to ~ 190 000
brain tumour-related deaths globally each year. Current therapeutic inter-
ventions consist of surgical resection followed by radiotherapy and temo-
zolomide chemotherapy, but average survival is typically around 1 year,
with < 10% of patients surviving more than 5 years. Recently, a fourth
treatment modality of intermediate-frequency low-intensity electric fields
[called tumour-treating fields (TTFields)] was clinically approved for
glioblastoma in some countries after it was found to increase median over-
all survival rates by ~ 5 months in a phase III randomised clinical trial.
However, beyond these treatments, attempts to establish more effective
therapies have yielded little improvement in survival for patients over the
last 50 years. This is in contrast to many other types of cancer and high-
lights glioblastoma as a recognised tumour of unmet clinical need. Previous
work has revealed that glioblastomas contain stem cell-like subpopulations
that exhibit heightened expression of DNA damage response (DDR) fac-
tors, contributing to therapy resistance and disease relapse. Given that
radiotherapy, chemotherapy and TTFields-based therapies all impact DDR
mechanisms, this Review will focus on our current knowledge of the role
of the DDR in glioblastoma biology and treatment. We also discuss the
potential of effective multimodal targeting of the DDR combined with
standard-of-care therapies, as well as emerging therapeutic targets, in pro-
viding much-needed improvements in survival rates for patients.
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1. Introduction
1.1. Glioblastoma and current treatment regimes
Brain tumours are globally responsible for around
190 000 deaths per year (around 5000 of which are in
the UK) and are responsible for the greatest reduction
in life expectancy of any cancer – around 20 years on
average [1,2]. Glioblastoma is ascribed the highest
glioma grade designated by the World Health Organi-
zation (WHO grade IV glioma). It is the most fre-
quently diagnosed primary brain tumour in adults and
is associated with an exceptionally poor clinical course
characterised by treatment resistance, rapid disease
progression and dire patient survival rates of around
12–15 months following diagnosis in clinical studies
[3]. However, average survival for unselected patients
in the real-world setting is typically closer to 8 months
[4]. In most cases, glioblastoma arises rapidly without
previous clinical presentation or histological confirma-
tion of a less malignant precursor lesion, although, in
a minority of cases, signs of progression from a lower
grade diffuse (WHO grade II) or anaplastic (WHO
grade III) astrocytoma are evident [5].
Despite some recent advances in the genetic, epige-
netic and molecular subtyping of gliomas [6], the cur-
rent standard-of-care treatment remains maximal safe
surgical resection followed by a course of radiotherapy
with concomitant and adjuvant chemotherapy [7–9].
The mainstay chemotherapeutic agent is oral delivery
of the DNA alkylating agent temozolomide following
successful clinical trial data evidencing a 2.5-month
increase in patient survival rates [7,8]. However,
despite this aggressive course of therapy, median
patient survival was estimated at 14.6 months, with
< 10% of patients surviving more than 5 years. Impor-
tantly, however, in the subset of patients with pro-
moter methylation of the DNA repair gene MGMT
(discussed below), the addition of temozolomide was
associated with overall survival of 21.7 months, repre-
senting an increase of 6.4 months [10]. More recent
studies corroborate the benefit of temozolomide in the
context of methylated MGMT status [11,12]. However,
in contrast, efforts to improve the survival of patients
with an unmethylated MGMT promoter have been less
successful [13,14].
Since the approval of temozolomide in 2005, no new
approved treatments for glioblastoma were forthcom-
ing until the recent development and clinical approval
of tumour-treating fields (TTFields) therapy, which
uses locoregional delivery of alternating electrical fields
within a narrow frequency range to specifically target
rapidly dividing cancer cells within a defined brain
region [15–17]. Akin to the introduction of temozolo-
mide into existing radiotherapy regimes, the inclusion
of TTFields to current temozolomide dosing schedules
increased overall patient survival rates by approxi-
mately 5 months, leading to clinical approval for
newly diagnosed glioblastoma by the Food and Drug
Administration (FDA) in the United States [17] in
2015, following its initial approval for recurrent
glioblastoma in 2011. However, the incorporation of
TTFields into standard-of-care therapy for glioblas-
toma is not universally accepted for numerous reasons,
including the lack of a placebo treatment, such as a
sham TTFields device, in key phase 3 randomised tri-
als [17,18]; incomplete understanding of the mechanis-
tic basis for TTFields therapeutic effects [16]; the
challenge of maintaining high treatment compliance;
and the current high financial costs associated with
this treatment regime. Consequently, opportunities for
patients to receive TTFields are not geographically
equitable and are largely dependent on the country’s
healthcare system approval structure for cancer thera-
pies [16]. Importantly, and relevant to this Review, the
current landscape of multimodal therapy used to treat
glioblastoma – that is, chemotherapy, radiotherapy
and TTFields – all induces DNA damage, replication
stress and mitotic-mediated cell death within tumour
cells. As such, a deeper understanding of the innate
DNA damage response (DDR) mechanisms and coor-
dinated cell cycle regulation within these tumours
offers opportunities to uncover exploitable tumour-
specific genetic and phenotypic vulnerabilities which
could lead to more efficient targeting and effective
treatment strategies in the clinic to confer much-
needed improvements in survival rates for patients.
1.2. Therapeutic challenges for glioblastoma
A cornerstone of glioblastoma treatment is effective sur-
gical resection of the tumour bulk. However, clinical
studies have suggested that neurosurgical removal of as
much as 98% of the tumour volume may be required
to provide an impact on median survival [19]. As such,
a plethora of surgical innovations have been applied to
help maximise surgical resection rates. Multimodal neu-
ronavigation, intraoperative magnetic resonance imag-
ing and ultrasound (MRI/US), and fluorescence-guided
surgery with 5-aminolevulinic acid (5-ALA) have
demonstrated the potential to augment surgical reduc-
tion of tumour burden [20–24]. Additionally, forthcom-
ing innovations, including the application of iKnife,
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which utilises rapid evaporative ionisation mass spec-
trometry (REIMS) to differentiate between tumour and
healthy tissue [25,26] or Raman spectroscopy, which is
used to achieve similar tumour-brain resolution in a
nondestructive manner [27–30], may yield further
improvements in resection rates in the near future.
However, given the highly infiltrative nature of glioblas-
toma and limited ability to resect infiltrated regions of
eloquent cortex without unacceptable morbidity, it is
unfortunately hard to envisage advances in surgical
technology impacting patient survival outcomes beyond
incremental gains.
In a similar manner to surgical interventions, radio-
therapy has also seen technological advancements,
including intensity-modulated radiation therapy,
stereotactic radiosurgery and proton beam therapy,
which have the potential to lead to improved delivery
of effective radiation doses to tumour sites whilst spar-
ing the surrounding healthy brain tissue [31,32].
Beyond the challenges associated with effective and
maximal surgical resection and targeted radiotherapy
regimes, delivery of a therapeutically effective dose of
chemotherapy to postsurgical residual tumour cells is
hampered by the presence of the blood–brain barrier/
blood–tumour barrier (BBB) [3,33], although there are
several groups developing ways in which to disrupt or
circumvent the BBB (discussed later).
The development of effective future therapies for
glioblastoma will also need to tackle the biological
mechanisms that help facilitate treatment resistance in
these aggressive cancers. Unlike lower grade tumours,
the majority of glioblastomas are classed as isocitrate
dehydrogenase (IDH) wild-type but often exhibit
mutations and/or deletions in phosphatase and tensin
homolog (PTEN), cyclin-dependent kinase inhibitor
2A/B (CDKN2A/B), telomerase reverse transcriptase
(TERT) promoter, tumour protein P53 (TP53), neu-
rofibromin 1 (NF1), phosphatidylinositol-4,5-bisphos-
phate 3-kinase catalytic subunit alpha (PIK3CA) and
phosphoinositide-3-kinase regulatory subunit 1
(PIK3R1), as well as amplification of epidermal growth
factor receptor (EGFR) and/or gain of chromosome 7,
chromosome 10 monosomy and MGMT promoter
methylation [5,34–36]. However, at present, no tar-
geted therapy designed to exploit such genetic and/or
phenotypic traits has proven successful within the
clinic [37]. One of the main reasons for this is that
glioblastomas exhibit profound intratumoural hetero-
geneity, with spatiotemporally divergent subpopula-
tions within a tumour displaying varying profiles of
vulnerability and resistance [38–41], which likely con-
tributes to local disease recurrence. Additionally,
increasing evidence supports the existence of a
subpopulation of glioblastoma cells that possess an
innate capacity for unlimited regeneration and self-re-
newal, which are often described as cancer stem cells
(CSCs) or glioblastoma stem cells (GSCs) [3,42–47].
Importantly, GSCs are often deemed responsible for
resistance to conventional chemoradiotherapy treat-
ment regimens through enhanced activation of DNA
damage checkpoints and DNA repair capacity [48–50].
This will be highlighted with specific examples later
within this Review.
1.3. Clinically relevant models of glioblastoma
Over the last decade, there has been a disappointing
lack of success in translating promising novel agents or
drug repurposing from preclinical studies into clinical
survival benefit for patients with glioblastoma [51]. To
some degree, this failure is representative of a lack of
clinically and postsurgically relevant preclinical models
of glioblastoma. In particular, the reported and further
emerging intratumoural heterogeneity that exists within
gliomas is a vital consideration for the development of
future therapies. Variation in the genetic aberrations,
phenotypic characteristics and clinical progression of
individual patient tumours presupposes the need for
personalised therapeutic strategies informed by a range
of molecular biomarkers [52–56]. Furthermore, accumu-
lating evidence suggests that a phylogenetic hierarchy of
spatiotemporally divergent subclones exists within indi-
vidual glioblastomas, each possessing a distinct collec-
tion of putative driver mutations and a characteristic
transcriptome [38,40,53,57,58]. Creating appropriate
preclinical models that are capable of recapitulating
such profound intratumoural heterogeneity as well as
GSC states represents a key challenge for the develop-
ment of new therapeutic agents that can impact patient
survival [3,46,59,60]. A detailed discussion of the advan-
tages and disadvantages of the various models is
beyond the scope of this Review, but these currently
consist of in vitro preclinical glioblastoma models that
range from traditional commercially available immor-
talised cell lines or fresh patient-derived primary cell
cultures (‘bulk’ or stem cell enriched) which can all be
maintained in either two- or three-dimensional (2D or
3D) architectures, as well as more complex tumouroid
and organoid cocultures and microfluidic ‘glioblastoma-
on-a-chip’ cultures [61–73]. Likewise, there are a
plethora of in vivo preclinical glioblastoma models
available, including subcutaneous, syngeneic, orthotopic
and patient-derived (PDX) xenografts as well as de novo
genetically engineered rodent models [74–77].
What is clear from the historic lack of newly
approved therapies and limited improvement in patient
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survival rates over the last 50 years compared with
other solid tumours is that glioblastoma represents a
complex and difficult therapeutic challenge. However,
recent work by numerous groups has started to reveal
further genetic and molecular insights into glioblas-
toma biology, particularly within the area of DDR
mechanisms that are triggered by current standard-of-
care radiochemotherapy regimes used to treat these
tumours. Furthermore, an evolving understanding of
the GSC niche together with the development of novel
preclinical models that better reflect postsurgical resid-
ual disease should hopefully begin to yield new thera-
peutic strategies over the next 5–10 years.
2. The DNA damage response and
glioblastoma treatment
2.1. Cellular responses to DNA damage
The structural integrity of DNA is constantly threat-
ened due to replication stress, telomere attrition and a
multitude of endogenous and exogenous agents that
generate high levels of varying DNA lesions. Such
agents include metabolic by-products, such as reactive
oxygen species (ROS) and aldehydes, UV light, ionis-
ing radiation (IR) and chemical toxins [78–80]. Failure
to repair DNA lesions induced by these processes can
lead to mutagenesis, tumorigenesis or cell attrition.
Given the potential deleterious effects on genome
integrity induced by such lesions, it is perhaps not sur-
prising that an intricate network of signalling path-
ways and reparative mechanisms have evolved to deal
with a plethora of DNA lesions, preserving genomic
architecture and integrity (genome stability). This net-
work is collectively referred to as the DNA damage
response (DDR), which encompasses a coordinated
and interconnected network of pathways that regulate
cell cycle progression/checkpoints, DNA repair mecha-
nisms, DNA replication and mitotic progression, as
well as transcriptional and cell death processes, in
order to preserve the integrity of the genome [79,81–
85]. Importantly, given that radiation and chemother-
apy treatments cause DNA lesions and affect cell cycle
progression, heightened and/or dysregulated DDR
mechanisms within tumour cells can often give rise to
innate and/or acquired treatment resistance. However,
such dysregulation to DDR mechanisms/processes dur-
ing cancer development and progression can also offer
vital cancer-selective vulnerabilities that can be
exploited for an improved therapeutic index as part of
either monotherapy- or combination therapy-targeted
treatment strategies [82,85–89].
The mechanisms associated with physically repairing
DNA damage can be categorised into four main types
based on the type of DNA lesion present: (a) base
modifications (including alkylation damage) and mis-
paired bases; (b) intrastrand or interstrand DNA
crosslinks; (c) single-strand breaks (SSBs); and (d)
double-strand breaks (DSBs) [79,81,84,85,90]. Addi-
tionally, although DSBs are often considered amongst
the most toxic of DNA lesions, it is worth considering
that each type of lesion is not an enduringly separate
entity. For example, radiation-induced damage often
leads to so-called ‘complex lesions’ or ‘clustered dam-
age’, in which multiple lesions are present within a few
hundred base pairs of the DNA helix [91]. The colli-
sion of replication forks with SSBs or DNA inter-
strand crosslinks (ICLs), particularly as a consequence
of oncogene activation, can result in the formation of
DSBs and other deleterious lesions. Similarly,
DNA : RNA hybrids known as R-loops can be gener-
ated from replication forks colliding with transcription
bubbles, which can have a plethora of deleterious
effects if not adequately resolved [92,93]. As such, the
dynamic relationships that exist between various DNA
lesions lead to functional redundancy within the repar-
ative processes, which likely contributes to treatment
resistance and forms the rationale for targeting multi-
ple DDR pathways/processes to potentially overcome
treatment resistance [78,82,83,86–89].
Maintenance of genome integrity relies not only on
accurate DNA repair, but also on the processes that
detect DNA damage and co-ordinate cell cycle check-
points, allowing time for DNA to be repaired. The
regulation of cell cycle checkpoints and subsequent
DNA repair processes as part of the early DDR pro-
cess is controlled by three main related protein kinases
– ataxia telangiectasia mutated (ATM); ataxia telang-
iectasia and Rad3-related kinase (ATR); and DNA-de-
pendent protein kinase (DNA-PK) – along with the
various cyclin-dependent kinases (CDKs) and the cen-
tral cell cycle regulator p53 and its associated factors
[83,90] (Fig. 1). ATM represents an apical, multifunc-
tional kinase within the DDR and typically plays a
key role in cellular responses to DNA DSBs, where it
helps co-ordinate all major cell cycle checkpoints via
the ATM-CHK2 axis [90,94]. Through the ATR-
CHK1 signalling axis, ATR helps preserve DNA integ-
rity in response to replication stress (perturbation to
ongoing replication forks) [95], although it is impor-
tant to note that there is significant crosstalk and some
functional redundancy amongst the activities of these
related kinases [90,96]. However, due to the main dif-
fering functions of these kinases, they are considered
as credible separate drug targets in cancer biology as
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part of either monotherapy or combinatorial (adju-
vant) therapeutic approaches [88,90,97,98].
Beyond the initial DDR signalling and cell cycle
checkpoint regulation, a key part of the cellular
responses to DNA damage is obviously the physical
repair of the vast array of DNA lesions that can be
present within both heterochromatic and euchromatic
regions of the genome [99–102]. An exhaustive discus-
sion of the vast array of DDR pathways is not possi-
ble within the confines of this Review; however, brief
summaries of some of the DNA repair pathways most
relevant to the therapy-induced DNA damage within
the context of glioblastoma treatment will be discussed
in the following section.
2.2. Therapy-induced DNA lesions and
associated repair mechanisms
Abrogation of the mechanisms that glioblastoma cells
use to repair the DNA lesions induced by chemo- and
radiotherapy may represent a key to effective multi-
modal treatment approaches [97] (Fig. 2). The most
effective chemotherapeutic agent in current standard-
of-care clinical use for glioblastoma is the alkylating
agent temozolomide [8]. Of the array of methylation
lesions induced on both nitrogen and oxygen mole-
cules within DNA nucleotides, O6-methlyguanine
(O6MeG) is considered the most toxic lesion induced
by temozolomide once metabolised from its prodrug
G1 S G2 M













Fig. 1. The role of ATM and ATR in cell cycle regulation following DNA damage. The processes of cell division (mitosis, M phase) and DNA
synthesis (S phase) are separated by two important gap phases (G1 and G2). Progression of mitotic cells through the cell cycle is controlled by
periodic accumulation and destruction of the aptly named cyclin-dependent kinases (CDKs) and cyclins. Inappropriate progression through
phases of the cell cycle is prevented by three main checkpoints (G1/S, intra-S and G2/M checkpoints; dashed red lines). Following DNA
damage, checkpoint activation is critical to provide ample time and recruit the necessary machinery required to maintain genomic integrity.
Checkpoint activation: DNA double-strand breaks (DSBs) activate the apical DNA damage response (DDR) kinase ataxia telangiectasia mutated
(ATM), which can influence all three major cell cycle checkpoints via the phosphorylation of checkpoint kinase 2 (CHK2) and subsequent
downstream signalling. In contrast, ataxia telangiectasia and Rad3-related kinase (ATR) is activated by the presence of replication protein A
(RPA)-coated single-stranded DNA (ssDNA) and contributes to maintenance of the intra-S phase and G2/M checkpoints via phosphorylation of
checkpoint kinase 1 (CHK1) and subsequent downstream signalling as indicated. G1/S checkpoint: Phosphorylation of p53 by CHK2 and ATM
directly (arrow not shown) results in a reduction in the binding of mouse double minute 2 homolog (MDM2) to p53 and p53 activation,
promoting its nuclear accumulation and stabilisation. Subsequently, elevated p53 levels promote increased transcription of p21, which inhibits
CDK2–cyclin-E activity, resulting in prevention of progression to S phase. Intra-S checkpoint: Within S phase, the activation of cell division cycle
25 (CDC25) phosphatases predominantly by prevention of cell division cycle 45 (CDC45) loading onto replication origins (preventing subsequent
DNA replication) primarily via the ATR–CHK1 axis, but also via ATM-CHK2-mediated phosphorylation of CDC25A, can instigate an intra-S
checkpoint in response to replication stress or other perturbations to optimal DNA synthesis, permitting a slowing of DNA replication. G2/M
checkpoint: Both ATM- and ATR-mediated phosphorylation of CHK2 and CHK1, respectively, lead to the phosphorylation of CDC25C
phosphatases, which influence the G2/M checkpoint via interaction with the cyclinB1–CDK1 complex. This figure is adapted, with permission,
from Ref. [227].
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form to MTIC [3-methyl-(triazen-1-yl)imidazole-4-car-
boxamide] [103]. O6MeG can act as a miscoding base
during DNA replication, leading to a corresponding
C-to-T transversion within the complementary DNA
strand. If O6MeG is not successfully excised by the
mismatch repair (MMR) DNA repair machinery [104],
it endures as a perpetually miscoding base, instigating
‘futile cycles’ of MMR with consequent stalling of
DNA replication forks or double-strand breakage
[104,105]. As such, MMR capacity within GSCs har-
bouring genetic or epigenetic defects that affect MMR
gene expression can impact on temozolomide
sensitivity as well as other phenotypic traits due to the
well-established hypermutation phenotype conferred
by MMR defects [106–108] (Fig. 2). Additionally, the
de-alkylating enzyme methylguanine methyltransferase
(MGMT) can sequester the methyl group from
O6MeG to restore the guanine residue to its original
state, but this leaves MGMT irreversibly inactivated
and subject to ubiquitin-mediated proteasomal degra-
dation [105,109]. Consequently, high expression levels
of MGMT can contribute to temozolomide resistance
in glioblastoma [109]. On the other hand, approxi-
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transcriptional repression of MGMT expression due to
hypermethylation of an MGMT-associated 5’ CpG
island, which confers a greater benefit from temozolo-
mide therapy and prolonged patient survival [10].
The mere notion that a DNA repair mechanism
such as MGMT expression can profoundly influence
survival for some patients provides further evidence of
the critical nature of DNA repair in glioblastoma.
However, it is important to note that, although both
MMR activity and MGMT expression can impact
temozolomide sensitivity of glioblastomas, longitudinal
genomic profiling has revealed that such defects do not
account for the majority of therapy resistance exhib-
ited within these tumours [106]. In addition to
O6MeG, the more prevalent (but less toxic) temozolo-
mide-induced DNA lesions N3-methyladenine and N7-
methylguanine are primarily removed via base excision
repair (BER), leaving an intermediary abasic [or apuri-
nic/apyrimidinic (AP)] site. The nucleotide gap is sub-
sequently filled through triggered DNA synthesis
processes and strand integrity restored through ligation
of the DNA ends – a process involving an AP endonu-
clease (APEX1), DNA polymerase (pol-b) and DNA
ligases I and III, respectively [110–112]. Additionally,
nucleotide excision repair (NER) is able to remove a
wide variety of structurally unrelated DNA lesions
that can be generated by both chemo- and radiother-
apy. The process can be activated by DNA helix dis-
tortions associated with structural changes to
nucleotides or by stalling of RNA polymerase II due
to the presence of a DNA lesion during transcript
elongation, and involves the DNA unwinding before
removal of a section of DNA containing the lesion fol-
lowed by resynthesis using the template strand and
subsequent ligation [113].
Radiotherapy exerts cellular damage by inducing a
wide range of DNA lesions, but it is particularly asso-
ciated with the generation of large amounts of SSBs
and DSBs (Fig. 2). Poly (ADP-ribose) polymerase-1
(PARP1) plays a pivotal role in detection of SSBs,
facilitating the colocalisation of the single-strand break
repair (SSBR) polypeptide x-ray repair cross-comple-
menting protein 1 (XRCC1) [114,115]. DNA DSBs are
predominantly repaired by the nonhomologous end
joining (NHEJ) and homologous recombination (HR)
DNA repair pathways. The HR pathway represents a
complex, high-fidelity mechanism of DNA DSB repair.
However, given its reliance on a homologous DNA
sequence (duplicate DNA strand on a sister chro-
matid) as a template for resynthesis of removed DNA
sequences around the site of DNA damage, HR-medi-
ated repair mechanisms are only possible during S and
Fig. 2. The effects of clinically approved therapies on the DNA damage response (DDR) and novel strategies to enhance efficacy of current
standard-of-care treatments. Schematic representation of the main DNA damage lesions (in blue italic) induced by therapies approved for
clinical use to treat glioblastoma and associated DDR mechanisms. For each approved treatment, putative strategies to enhance therapeutic
efficacy through targeting relevant DDR mechanism(s) are indicated. (A) Radiotherapy: generates large amounts of DNA single-strand breaks
(SSBs) and double-strand breaks (DSBs), which activate ATR and ATM, respectively. DSB repair is then predominantly undertaken by either
nonhomologous end joining (NHEJ), which is available throughout the cell cycle but compromises fidelity, or homologous recombination
(HR) DNA repair, which provides a high-fidelity repair mechanism, but is only available during S and G2 phases of the cell cycle due to the
requirement for a sister chromatid. SSB repair relies on PARP1 to detect SSBs and facilitate the recruitment of XRCC1. However, the
presence of strand breaks also leads to stalling of DNA replication forks, which depend on the functions of ATR and proteins within the
Fanconi anaemia pathway (FAP) for stability and replication restart. Consequently, a strong scientific rationale exists supporting inhibition of
either ATM (ATMi), ATR (ATRi), PARP1 (PARPi) or the FAP (FAPi) to enhance the efficacy of radiotherapy. (B) Temozolomide: produces an
array of methylation lesions including N3-methyladenine (N3MeA) and N7-methylguanine (N7MeG), which are substrates for effective
removal via DNA base excision repair (BER), and O6-methylguanine (O6MeG), which is removed directly by the enzyme MGMT in a suicide
reaction. Hypermethylation of the MGMT gene promoter region leads to reduced MGMT expression, shifting the balance in favour of
persistent O6MeG. O6MeG can act as a miscoding base during DNA replication, leading to a corresponding C-to-T transversion within the
complementary DNA strand. If O6MeG is not successfully excised by the mismatch repair (MMR) DNA repair machinery, it endures as a
perpetually miscoding base, instigating ‘futile cycles’ of MMR with consequent stalling of DNA replication forks or DSBs. (C) Tumour-
treating fields (TTFields): may negatively impact FAP and HR-mediated DNA repair processes. TTFields-induced ‘BRCAness’ (reflecting a
relative HR deficiency) provides a compelling rationale to combine this therapeutic modality with PARPi, or potentially FAPi, ATRi or even
ATMi. (D) Carmustine (BCNU) – Gliadel wafers: provide local delivery of this bidirectional DNA alkylating agent, leading to the generation of
DNA interstrand crosslinks which impede DNA replication during S phase. This leads to activation of the FAP, within which
monoubiquitination of FANCD2 within the FANCD2-I complex is a key quantifiable step. Activated FANCD2-I coalesces as foci at sites of
DNA damage and acts as a master regulator of downstream DNA repair, recruiting proteins involved in nucleotide excision repair (NER),
translesion synthesis (TLS) and HR. Interplay with associated DDR mechanisms, for example ATM and ATR, leads to the phosphorylation of
multiple FAP proteins (examples indicated), providing a rationale for the use of non-FAP DDR inhibitors (e.g. ATRi or ATMi) to sensitise to
crosslinking chemotherapy, and for the concept of combining multiple DDR inhibitors (including FAPi) to potentially maximise therapeutic
enhancement.
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G2 phases of the cell cycle, when such sister chro-
matids are available [116,117]. Interestingly, although
TTFields therapy does not directly induce DNA
breaks (unlike IR), recent work has suggested that, in
addition to its effects on mitotic cells, TTFields may
negatively impact on HR-mediated DNA repair pro-
cesses [16,118], which could be important for future
DDR-targeting strategies that combine with this
recently approved glioblastoma therapy. In contrast to
HR, the NHEJ DNA repair pathway provides rapid
DSB repair capabilities throughout the cell cycle (since
a homologous sister chromatid is not required), per-
mitting repair of a range of DNA-end configurations
(Fig. 2). However, the flexibility and rapidity of NHEJ
is provided at the expense of fidelity [119,120]. As one
might expect given the cell cycle regulated nature of
these pathways, both HR and NHEJ are tightly regu-
lated by CDK activity [120,121], a family of kinases
often dysregulated in human cancers [122,123].
Finally, the Fanconi anaemia (FA or FA/BRCA)
pathway is frequently activated in response to DNA
strand breaks, alkylation damage and other cytotoxic
DNA lesions induced by both alkylating and DNA
crosslinking chemotherapeutic agents that impede
ongoing DNA replication [124–128]. The FA pathway
is also activated during normal S-phase progression
and is regulated by both ATM and ATR kinases [124–
134]. The FA pathway consists of at least 22 proteins
which can be broadly categorised into three distinct
functional groups (core complex, ID complex and
downstream effectors) that, through sequential interac-
tion, facilitate lesion repair and the restart of replica-
tion forks via physical removal of lesions by NER and
HR-mediated processes, as well as interactions with
components of the MMR system [135].
3. Targeting functional interplay
within the glioblastoma DDR network
3.1. Exploiting synthetic lethality and synthetic
sensitivity strategies
As mentioned previously, there are a plethora of inter-
connected interactions and functional crosstalk
between the various DDR, regulatory and DNA repair
pathways that open up a multitude of potential thera-
peutic targeting strategies in heterogeneous tumours
such as glioblastoma [88]. Perhaps most notable over
the past 10 years or so is the concept of synthetic
lethality: a concept that was originally described as a
simultaneous genetic mutation in, or functional aberra-
tion of the product of, two genes which causes cell
death; but in isolation, either change is survivable
[136]. More recently, synthetic lethality in terms of
oncology-based therapeutic strategies has expanded to
include scenarios in which specific phenotypic traits
such as defective HR-mediated DNA repair function,
or aberration in the function of certain genes or path-
ways, result in impaired cell growth or proliferation,
promoting lethal effects in the presence of additional
insults such as IR or cytotoxic chemotherapy [137]. As
such, the term ‘synthetic sensitivity or lethality’ (SSL)
can be used to amalgamate these related concepts.
Although major advancements in the generation of
RNAi and CRISPR/Cas9 libraries have undoubtedly
advanced our ability to uncover potential SSL rela-
tionships at the genome scale, the most successful
implementation of an SSL strategy to date in cancer
treatment, the targeting of BRCA-deficient cells with
PARP1 inhibitors, was derived from hypothesis-dri-
ven research rooted in a fundamental understanding
of the specific molecular pathways concerned and rel-
evant interplay between them, rather than broad
screening approaches [138,139]. This seminal work
has led to a wave of clinical approvals for PARP1
inhibitors that are delivering survival benefits to
patients with a range of cancers globally [140–142]. In
the context of gliomas, tumours with IDH1/2 muta-
tions may exhibit a ‘BRCAness’ phenotype as a con-
sequence of inhibition of HR DNA repair processes
by the enhanced levels of oncometabolites, which
could explain why a subset of IDH-mutant tumours
respond well to conventional DNA damaging
chemotherapies such as temozolomide as well as
PARP1 and ATR inhibitors [141,143,144]. However,
as highlighted earlier, the majority of high-grade
aggressive gliomas do not exhibit such defects in IDH
genes and associated metabolism but, as discussed
below, disruption to HR and associated DDR path-
ways may represent a credible mechanism to produce
a similar phenotype in these tumours. Furthermore,
challenges in efficient delivery of such compounds
across the BBB are a major clinical consideration;
however, at least for PARP1 inhibitors, early indica-
tions are encouraging in that therapeutically active
doses can be achieved at the tumour site [145].
3.2. Single DDR inhibitor strategies to enhance
therapeutic response
As mentioned previously, glioblastoma cells within a
single tumour can demonstrate remarkable hetero-
geneity in the expression of DDR factors and conse-
quently exhibit varying resistance profiles [146,147],
which likely plays a key role in treatment failure.
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Given the interconnected nature of the DDR path-
ways [88], it is perhaps not surprising that, although
promising in preclinical models, targeting any single
DDR pathway might not yield an effective therapeu-
tic response clinically. The D’Andrea group were the
first to demonstrate that components of the FA path-
way could confer resistance to temozolomide in
glioma cells [148], which was further corroborated by
Kondo and colleagues [149]. Building upon these
findings, we showed that the FA pathway is re-ex-
pressed and active within high-grade gliomas com-
pared with low-grade tumours as well as normal
healthy tissue and that inhibition of the FA pathway
in both established and primary glioma cells could
confer an increased sensitivity to temozolomide [150].
These findings were recently confirmed by large-scale
CRISPR-Cas9 screens that identified the FA and
related HR pathways as key modulators of temozolo-
mide resistance within glioma stem cells [108]. Impor-
tantly, we showed that disruption to FA pathway
function was able to render glioma cells sensitive to
temozolomide irrespective of MGMT status/expres-
sion levels [150], demonstrating a potential large
scope for such an approach within the clinical setting.
This is particularly important, as PARP1 inhibition
(the most successful DDR-targeting drug to date)
may only confer a similar increased temozolomide
sensitivity within cells that have MGMT promoter
methylation [151], which represents ~ 40% of all
patients diagnosed with glioblastoma and whose
tumours are already intrinsically more sensitive to
temozolomide. This is consistent with previous work
by Gupta and colleagues, who demonstrated that
siRNA-mediated knockdown of either N-methylpur-
ine DNA glycosylase (MPG) or XRCC1 (two indis-
pensable components of a functional BER pathway)
did not confer temozolomide sensitivity in resistant
glioma cell lines [152], even though PARP1 can act as
a scaffold to promote BER-mediated repair of alkyla-
tion damage [153].
Given that persistent bulky O6MeG lesions in the
absence of MGMT result in elevated DNA replication
stress [154,155] and that replication fork stability and
recovery is influenced by a number of DDR factors,
such as PARP1, as well as the HR and FA proteins
RAD51/FANCR, FANCD2, BRCA1/FANCS and
BRCA2/FANCD1, the integrity of some of these inter-
connected DDR processes may underpin the heteroge-
neous preclinical success of PARP1 inhibitor-mediated
temozolomide sensitisation. At least theoretically, these
data would support the use of adding an additional
DDR inhibitor to maximise replication fork collapse
and/or failure of resultant DNA DSB resolution,
potentially resulting in more pronounced neoplastic
cell death across a wider range of tumours. In this
regard, it seems rational that the activity of apical
DDR kinases, such as ATR and ATM, that regulate
replication stress signalling and DNA break repair
mechanisms might cooperate to limit the cytotoxicity
of temozolomide in cancer cells. Interestingly, activa-
tion of both ATR and ATM following temozolomide
chemotherapy occurs in an MMR-dependent manner
[156], which likely reflects the nature of the cytotoxicity
associated with O6meG compared with N7-meG and
N3-meA lesions, which do not activate MMR. Previous
work by Eich and colleagues showed that siRNA-medi-
ated knockdown of either ATR or ATM sensitised an
MGMT-negative glioma cell line to temozolomide
[157], with similar findings for ATM also reported by
Nadkarni et al. [158]. Interestingly, the degree of sensiti-
sation conferred by ATR knockdown in the Eich study
was more than double that observed following ATM
siRNA, indicating that impaired resolution of DNA
replication stress generated from O6MeG lesions may
be a key driver of sensitisation in this context, especially
given that simultaneous ATR and ATM knockdown
did not provide any additional sensitisation relative to
ATR alone and that the enhanced temozolomide sensi-
tisation could be rescued by ectopic expression of
MGMT [157]. These findings were also recently corrob-
orated by Jackson et al., who established that MGMT-
deficient glioma cells are profoundly susceptible to
temozolomide sensitisation using small-molecule ATR
inhibitors both in vitro and in vivo [159].
3.3. The FA pathway as a foundation for future
DDR-centric combinatorial strategies
In addition to potential compounding genetic and/or
epigenetic alterations within glioblastomas that might
affect DDR-targeting strategies, and the interplay
within the BER, MMR, MGMT, FA and HR path-
ways (highlighted above), interactions between the FA
pathway and other DDR elements have been charac-
terised that are also important to consider with regard
to potential FA-based combination targeting strategies
within glioblastomas [160]. For example, as mentioned
previously, both ATM and ATR phosphorylate several
proteins within the various FA subcomplexes [161–
163] and components of the FA pathway have also
been shown to promote activation of ATR and supress
potentially deleterious repair of DNA ICLs by NHEJ
[164–166]. Additionally, as the FA pathway promotes
HR-mediated DNA repair processes around
stalled/collapsed replication forks [167], HR-deficient
cells have been shown to be sensitive to disruption of
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FA pathway function [168,169]. Given this functional
interplay, it has been postulated that FA dysfunctional
tumours, or targeting of the FA pathway, may render
them sensitive to PARP1 inhibitors [170–172], as well
as a multitude of other drug targeting strategies within
the FA and related DDR pathways [170]. Indeed, we
have recently generated data in clinically relevant GSC
3D cell culture model systems highlighting profound
radio- and chemosensitisation through the combined
targeting of the FA pathway in combination with
ATM, ATR or PARP1 inhibitors (Rominiyi et al,
manuscript under preparation).
Unfortunately, there have been no reported ration-
ally designed inhibitors of the FA pathway to date;
however, recent structural insights into key regulatory
components of the FA pathway together with current
efforts by several groups to identify FA pathway inhi-
bitors (including our own group) [173–178] should
hopefully lead to the emergence and further develop-
ment of such compounds in the near future that could
be of great clinical significance for glioblastoma treat-
ment regimes. Apart from exhibiting high potency and
specify, such compounds would also need to demon-
strate high biological efficacy within the correct brain
regions or be adaptable to novel delivery mechanisms
in order to maximise their effectiveness in any such
therapeutic regimes [3]. Encouragingly, tumour margin
penetration within a biologically active drug concen-
tration range has been recently reported for the
PARP1 inhibitor olaparib (Lynparza) in combination
with temozolomide chemotherapy as part of the
OPARATIC trial [145], and it will be interesting to see
the results from other DDR inhibitor trials for
glioblastoma when they are reported (Table 1).
3.4. Expanding the preclinical evidence base for
parallel targeting of the DDR
As highlighted previously, there has been intense
research into the development of small-molecule inhi-
bitors of DDR proteins [82]; to date, however, only a
handful of published preclinical studies have examined
combined inhibition of multiple DDR elements simul-
taneously in glioblastoma. Given that ATM and
PARP1 inhibition each individually possess some util-
ity in sensitising GSCs to radiotherapy [179,180],
Ahmed et al. [181] investigated parallel inhibition of
the DDR targets ATM, ATR, CHK1 and PARP1 in
primary patient-derived glioblastoma cell lines. Firstly,
in agreement with previous findings by Bao et al. [48],
this study demonstrated that these DDR factors were
upregulated in the inherently treatment-resistant sub-
population of GSCs compared to bulk populations.
This further confirms the importance of targeting mul-
tiple DDR pathways and the potential for functional
redundancy within the DDR to contribute to the treat-
ment-refractory nature of glioblastoma. Secondly, the
study by Ahmed et al. demonstrated that combined
inhibition of PARP1 and ATR resulted in a profound
radiosensitisation of GSCs, with effects greater than
any single inhibitor used in isolation [181].
The rationale for a combination DDR inhibitory
strategy in glioblastoma is also supported by the work
of Signore and colleagues, who performed a simultane-
ous multipathway approach with subsequent reverse-
phase protein microarrays and kinase inhibitor library
screening to identify dual inhibition of CHK1 and
PDK1, resulted in profound retardation of GSC growth
in both in vitro and in vivo (subcutaneous and intracra-
nial mouse) models [182]. Although this study is highly
informative, the lack of target specificity with use of a
drug such as UCN-01 severely limits potential clinical
utility due to the high likelihood of dose-limiting toxici-
ties mediated by known off-target effects associated with
this compound. Nevertheless, this work provides further
preclinical proof-of-concept data in support of such
combinatorial approaches within heterogeneous glioblas-
toma tumour populations. More recently, Rasmussen
et al. [183] demonstrated that reduced DDR capacity
through PARP1 inhibition (olaparib) in conjunction
with epigenetic-downregulation-induced oxidative stress
through histone deacetylase (HDAC) inhibition
(vorinostat) led to reduced glioblastoma cell survival,
induced apoptosis and impaired cell cycle progression.
As demonstrated through these examples, the princi-
ple of multimodal targeting within the DDR network
based on an in-depth mechanistic understanding of
functional interplay and regulatory mechanisms offers
a potentially powerful approach to combat biological
complexity and functional redundancy within the
DDR, as well as intratumour heterogeneity within
glioblastoma tumour subpopulations (Fig. 3). Indeed,
preclinical research investigating such dual DDR inhi-
bition approaches outside of glioblastoma research is
supportive of this concept, for example CHK1 and
PARP1 inhibition in pancreatic cancer [184], CHK2
and PARP1 inhibition in lymphoma [185], CHK1 and
PARP1 inhibition in breast cancer [186], ATR and
PARP1 inhibition in breast and ovarian cancer [187],
and ATM and PARP1 inhibition in lung cancer [188].
3.5. Indirect DDR-targeting strategies in
glioblastoma
In addition to direct combination targeting of DDR
network factors, a comparable approach can be to
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Table 1. DNA damage response inhibitor trials in high-grade glioma. AEs(G3-4), grade 3–4 adverse events; AEs, adverse events; and WBRT, whole brain radiotherapy; CR, complete
response; DIPG, diffuse intrinsic pontine glioma; DLTs, dose-limiting toxicities; EFS, event-free survival; F/U, follow-up; IMRT, intensity-modulated radiation therapy; IR, radiotherapy; MTD,
maximum tolerated dose; nGBM, newly diagnosed GBM; NIRA, niraparib; OLAP, olaparib; ORR, overall response rate (proportion of patients with a PR or CR); OS, median overall survival;
PAMI, pamiparib; PFS, median progression-free survival; PR, partial response; QoL, quality of life; rGBM, recurrent GBM; rHGG, recurrent high-grade glioma; RP2D, recommended phase
II dose – highest dose with acceptable toxicity (producing a rate of around 20% DLTs); Rx, treatment; SAEs, severe adverse events; SD, stable disease; SoC, standard-of-care; TALA,
talazoparib; TMZ, temozolomide; TTF, tumour-treating fields; VELI, veliparib.
Trial (reference) & indication
Design &
n (rec dates) Treatment(s) 1° Endpoint 2° Endpoint(s)
Results/remarks &
conclusions




Veliparib (ABT-888), radiation therapy,
and temozolomide in treating patients






VELI + IR + TMZ Phase I: VELI MTD
Phase II: OS (with
VELI MTD)
A) Safety/toxicity
B) Pharmacokinetics  Following initial safety groups
and planned dosing steps,
3/6 pts (50%) had DLTs (2
thrombocytopenia,
1 neutropenia) with 10mg BD
VELI+R+TMZ ? accrual
discontinued
 VELI at this dose with
standard dosing regimen
of IR+TMZ deemed not
tolerable





Olaparib and temozolomide in treating






Stage I: OLAP for 3/7
prior to surgery then
usual Rx
Stage II: Escalating OLAP
3/7 prior to surgery then









of OLAP + TMZ
 OLAP detected in 73/74
tumour specimens from
27 pts, mean conc.
588nM (range = 97–1374 nM).
 Mean tumour margin :
core ratio = 1.2 (0.2–3.9)
 Mean tumour : plasma
ratio = 0.25 (0.01–0.9)
 24/35 pts (67%) AEs(G3-4)
 45% PFS at 6 m F/U
 OLAP penetrates tumour







NIRA + TMZ No. of DLTs A) ORR within
30 days of  MTD & RP2D = 40 mg OD

































































































































































Trial (reference) & indication
Design &
n (rec dates) Treatment(s) 1° Endpoint 2° Endpoint(s)
Results/remarks &
conclusions
Niraparib (MK-4827) given with temozolomide
in participants with advanced cancer
(2011–2012) last dose & 2m
intervals
B) PFS
 2/10 pts (20%) had Grade
4 thrombocytopenia at this
dose
 1 PR (glioblastoma) & 2 SD
out of 16 evaluable pts
 NIRA tolerable in combination
with TMZ
nGBM [231]
Two parallel phase I studies of olaparib and
radiotherapy or olaparib and radiotherapy
plus temozolomide in patients with newly
diagnosed glioblastoma, with treatment















(+/ TMZ)  MGMT methylated dosing
schedule = OLAP (dose
escalation) with IR and
concomitant TMZ, then
4 weeks OLAP with
maintenance TMZ started
after completing OLAP





A randomized phase I/II study of veliparib
(ABT-888) in combination with










Arm 1: VELI + TMZ
75 mgm2 (both
21/28 day cycle)
Arm 2: VELI + TMZ
150 mgm2
(both 5/28 day cycle)
Phase I: MTD.
Phase II: PFS at 6m
A) ORR
B) OS  Myelosuppression AE
(G3-4) in
20% of pts
 PFS at 6 m = 17.0% (BEV-N)
& 4.4% (BEV-R) – median
PFS ~ 2 m (95% CI,
1.9–2.1 m) in both groups
 Median OS = 10.3 m
(8.4–12.0 m, BEV-N) & 4.7 m
(3.5–5.6 m, BEV-R)
 Concluded addition of VELI
‘did not significantly improve
PFS at 6m’ relative to historic
controls




Veliparib, radiation therapy, and
temozolomide in treating younger patients












































































































































































Trial (reference) & indication
Design &
n (rec dates) Treatment(s) 1° Endpoint 2° Endpoint(s)
Results/remarks &
conclusions
gliomas: a paediatric brain tumor
consortium study
 Day 4 average VELI
(65 mgm2) plasma
Cmax = 3 lM
 VELI DLTs inc: intratumoural
haemorrhage (1 pt, Grade 2);
rash (2 pts, Grade 3);
neurological (1 pt, Grade 3)
 Additional intrapatient TMZ
dose escalation could not be
tolerated
 OS at 1 and 2 years = 37.2%
and 5.3% respectively
 Accrual stopped early due to
futility at interim analysis
NCT02116777 [234]
Solid & haematological cancers
Talazoparib and temozolomide in treating












A) ORR all solid
tumours
(RECIST)
 RP2D = TALA 600 lgm2 BD
on day 1 then OD days 2–6/28
with TMZ 30 mgm2 day
2–6/28 cycle
 Majority of patients had
Ewing sarcoma (EWS), but
one patient with a malignant
glioma experienced a PR
 During Phase II, no response
observed out of 10 EWS pts
 No efficacy in EWS but may




Pamiparib (BGB-290) with radiation and/or








Arm 1: PAMI + IR
Arm 2: PAMI + IR + TMZ
rGBM (un- & methylated)








 RP2D for Arm 1 = PAMI
60 mg BD for 6 weeks
alongside IR
 RP2D for Arm 3 = PAMI
60 mg BD day 1–28 + TMZ
60 mgm2 7/28 day cycle
 Well tolerated – no Grade 4/5
toxicities; Grade 3 – Arm

































































































































































Trial (reference) & indication
Design &
n (rec dates) Treatment(s) 1° Endpoint 2° Endpoint(s)
Results/remarks &
conclusions
2 – decreased WBC count
(11%). Arm 3 none
 PAMI + IR + TMZ well
tolerated – trial ongoing
– recruitment ends October
2021, final results awaited
NCT03212742 [236]
Unresectable HGG
Study of concomitant radiotherapy with



















 Dosing schedule = OLAP
(IR-period dose) with IR and
concomitant TMZ, then
4 weeks OLAP at same
dose ? then maintenance
TMZ started alongside daily
OLAP (maintenance dose)





Cediranib maleate and olaparib compared















 Dosing schedule = OLAP
BD on day 1–28/28 cycle
with cediranib OD on day
1–28/28 cycle
 Trial ongoing – recruitment
completed May 2020, results
awaited (estimated study
completion date May 2021)
NCT03233204
Solid tumours with DDR defects
Phase 2 subprotocol of olaparib in patients
with tumors harbouring defects in DNA
damage repair genes (NCI-COG Paediatric












assignment from within the
overall paediatric MATCH
study [237] – based on
actionable mutations
 Eligible actionable mutations
not defined at trial registration
 Dosing schedule = OLAP BD
on day 1–28/28 cycle
 Changes in tumour genomic

































































































































































Trial (reference) & indication
Design &
n (rec dates) Treatment(s) 1° Endpoint 2° Endpoint(s)
Results/remarks &
conclusions
 Trial ongoing – recruitment
ends September 2024
NCT03212274
rGlioma (WHO Grade II-IV) /
cholangiocarcinoma / solid tumours
with IDH1/2 mutation
Olaparib in treating patients with advanced
glioma, cholangiocarcinoma, or solid tumours



















 Dosing schedule = OLAP BD
on day 1–28/28 cycle
 Builds on preclinical studies
demonstrating ‘BRCAness’
with IDH1/2 mutation and
elevated 2HG [238]
 Trial ongoing – recruitment




Veliparib (ABT-888), radiation therapy, and
temozolomide in treating patients
with newly diagnosed malignant








VELI + IR + TMZ PFS A) ORR
B) OS  Dosing schedule = daily
VELI BD during
chemoradiotherapy phase
then 4 weeks after
completion ? daily VELI BD +




 Exploratory objectives inc:
relationship between BRCA
1/2 alternations and features
of HRD (inc. large-scale
translocations, mutational
signature 3); penetrance of
HRD genes inc. HR genes,
FA genes, ATM, CHK2, and
MMR genes




Evaluating the efficacy and safety



















 Cohort 1: initiate and continue
TTFields for 5–7 days prior
to starting NIRA
 Cohort 2: receive TTFields

































































































































































Trial (reference) & indication
Design &





 Builds on preclinical studies
demonstrating ‘BRCAness’
induced by TTFields [118,239]










OLAP only PFS n/a
 Dosing schedule = OLAP
300 mg BD on days 1–28/28
cycle
 Based on preclinical studies
demonstrating ‘BRCAness’
with IDH1/2 mutation and
elevated 2HG [238]




Olaparib and durvalumab in patients with














 Dosing schedule = OLAP BD
on days 1–28/28 cycle +
durvalumab (anti-PD-L1
therapy) on day 1/28 cycle
 Based on preclinical studies
demonstrating ‘BRCAness’
with IDH1/2 mutation and
elevated 2HG [238]






nGBM (MGMT promoter hypermethylated)
Temozolomide with or without veliparib in







After SoC IR and
concomitant TMZ:
Arm 1: VELI + TMZ









 Patients permitted to receive
TTFields alongside trial
therapies. No other additional
therapies permitted


































































































































































Trial (reference) & indication
Design &
n (rec dates) Treatment(s) 1° Endpoint 2° Endpoint(s)
Results/remarks &
conclusions
alternations to DDR genes
influence outcomes
 Trial ongoing – recruitment
completed November 2020,
results awaited
Summary of key ATM inhibitor in high-grade




Safety and tolerability of AZD1390 given







AZD1390 + SoC IR:
nGBM: IMRT 60 Gy
over 6 weeks
rGBM: IMRT 35 Gy over
2 weeks





 Dosing schedule = AZD1390
administered in 3 ‘cycles’
– (1) 1 dose prior to starting
IR; (2) intermittent if
continuous administration
during IR; (3) 2-week adjuvant
ATMi after IR
 Based on preclinical studies
demonstrating BBB
penetration and improved
survival with AZD1390 in
mouse models [243]
 Trial ongoing – expected
completion February 2023











After SoC IR and
concomitant TMZ:
Arm 1: TMZ
Arm 2: Neratinib + TMZ
Arm 3: CC115 + TMZ





 Compares SoC therapy with
3 novel regimens each






 Details on CC115 dosing
schedule not available


































































































































































Trial (reference) & indication
Design &
n (rec dates) Treatment(s) 1° Endpoint 2° Endpoint(s)
Results/remarks &
conclusions










Single dose of AZD1775
(100mg, 200mg or






analysis  Mean peak total AZD1775
plasma concentration over
100 ngmL1 with single
200 mg or 400 mg dose
 Mean unbound AZD1775
tumour concentration of
85 ngg1 at 2–24 h
exceeding the in vitro IC50
(40 ngmL1) for WEE1
inhibition
 Confirmation of target effects
including elevated cH2AX,
pH3 and cleaved caspase-3
NCT01849146 [244]
nGBM/rGBM
Adavosertib (AZD1775), radiation therapy,
and temozolomide in treating patients with






Arm 1: AZD1775 during
initial IR + TMZ and
maintenance TMZ





B) PFS  Preliminary data suggests
AZD1775 in combination
with initial IR + TMZ at
150 mg QDS and 425 mg
QDS alongside maintenance
TMZ for 5 days in each
28 day cycle had acceptable
toxicity
 Trial recruitment completed

































































































































































target other signalling pathways that impact on DDR
activity and/or capacity. For example, Gomez-Roman
et al. [64] recently demonstrated in 3D GSC models
that disruption to functional VEGF and AKT sig-
nalling pathways impacted the balance between NHEJ
and HR DNA DSB break repair activities to increase
radiation sensitivity. This is particularly interesting
given that targeted therapies against VEGF (such as
bevacizumab) have generally failed to improve patient
overall survival in large clinical trials [51].
In a similar manner to identifying nonclassical DDR
pathway targeting strategies, we recently identified
ERK5/MAPK5 through a kinome-wide RNAi screen
as a novel temozolomide resistance factor, with abroga-
tion of ERK5 activity in glioma cells leading to defec-
tive DNA repair capacity, likely through inappropriate
NHEJ activity prior to mitosis [189]. Interestingly,
ERK5 has recently been identified as a key factor in
promoting cell growth and cell survival in the aggressive
diffuse intrinsic pontine gliomas [190], supporting recent
evidence around ERK5 as an emerging novel oncology
drug target [191–193]. As such, we are currently further
assessing the potential of ERK5 targeting in glioblas-
tomas as part of various combinatorial approaches
together with current standard-of-care therapy.
On the topic on non-DDR signalling kinases that
impact the DDR, Riess et al. [194] recently assessed
targeting of the CDK family of signalling kinases given
their common dysregulation in glioblastoma and the
recent advancement of a new generation of clinically
approved compounds. Using a CDK-based monother-
apy approach in various 3D glioblastoma preclinical
models, they showed that CDK inhibitors could nega-
tively affect tumour growth, but also that some CDK
inhibitors were able to effectively combine with DNA
damaging regimes such as radiation and temozolomide
treatments. However, they also showed that not all
tested CDK inhibitors behaved in the same way, with
some conferring antagonistic properties when combined
with temozolomide, potentially through differential
effects on global gene expression patterns [194]. This
study further highlights the need to understand the
intricate functional interplay and regulatory mecha-
nisms within the DDR as part of preclinical studies to
help maximise the therapeutic potential of such new
combinatorial regimes within the clinic.
In addition to CDK dysregulation, another common
feature of cancer cells is a heightened level of replica-
tion stress due to the activation of oncogenes [92,195].
Oncogene-induced replication stress has been shown to
be present in GSCs [49] and is capable of triggering
the DDR during early tumorigenesis [196]. Recent
work from Ning et al. [197] revealed that heightened
























































Fig. 3. An approach for cancer-selective killing through multimodality targeting of interconnected DNA damage response (DDR) pathways. A
schematic representation of simultaneous targeting of multiple interconnected DDR processes to achieve cancer-selective killing. Left – a
simplified network schematic of key DDR proteins illustrating the complexity of intra- and interpathway protein–protein interactions within
the global DDR. This complexity provides a degree of functional redundancy in DDR processes, which is likely to afford therapeutic
resistance to current DNA damaging therapies. Right – due to the loss of functionality within some DDR pathways during carcinogenesis,
cancerous cells often demonstrate overreliance on a reduced subset of DDR processes for cell survival. Where inhibition of a single DDR
pathway may not be sufficient to provide synthetic lethality or substantial cancer cell killing, targeting multiple DDR processes
simultaneously may overwhelm the remaining functional DDR leading to exquisitely potent cancer cell killing. However, by virtue of their
complete repertoire of fully functional DDR processes, normal cells might continue to avoid significant toxicity associated with multi-DDR-
targeting strategies (e.g. PARPi in noncancerous breast tissue that exhibits normal BRCA1/2 expression/function).
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ATR-mediated replication stress signalling through
transcriptional repression of CDK18. This is consistent
with recent findings from our laboratory that identified
CDK18 as a novel component of the ATR-mediated
replication stress signalling module that promotes cel-
lular resistance to a variety of replication stress-induc-
ing chemotherapeutic agents [198,199]. In keeping with
the aforementioned interplay between ATR signalling
and PARP1 activity (see above), Ning et al. [197] fur-
ther showed that GSCs with reduced CDK18 expres-
sion and subsequent retarded ATR activity, as a
consequence of oncogenic MYC action, were rendered
sensitive to PARP1 inhibitors. In keeping with a
heightened S-phase fraction within a subpopulation of
GSCs, a recent study by Zhou et al. [200] showed that
purine metabolism was increased in aggressive/high-
grade tumours and represents a potential target to
improve the effectiveness of radiotherapy regimes. This
is especially compelling given that, as highlighted
within this study, there are currently FDA-approved
inhibitors of GTP synthesis, although obviously the
efficient delivery of therapeutic doses within the brain
will be key to the success of such strategies.
Finally, another common feature of cancer cells,
particularly solid tumours, is an imbalance between
oxygen supply and demand from active aerobic meta-
bolism, causing regional hypoxia defined as regions of
reduced oxygen concentration. This presents both chal-
lenges in terms of cell death mechanisms, which are
less effective in the context of hypoxia, such as those
elicited by radiotherapy, but also potentially exploita-
ble therapeutic opportunities given the effects hypoxia
has on several DDR factors [201–204]. Recent discov-
eries outside of glioblastoma have revealed key molec-
ular and functional links between the DDR,
replication stress signalling and the cGAS-STING
immune pathways [205,206], and that targeting of
replication stress signalling may synergise with
immuno-oncology (IO) therapies [207,208]. However,
the propensity of glioblastoma to escape immuno-
surveillance, potentially poor receptor expression and
anatomical considerations have so far limited progress
in the development of effective immunotherapies for
glioblastoma compared to other cancers [209–212].
However, strategies to circumvent such immuno-
surveillance escape in gliomas have recently been
reported [213] and, as more mechanistic understanding
around how these pathways interact becomes avail-
able, further therapeutic opportunities for gliomas will
hopefully be developed. Together, these studies raise
the possibility that oncogene-induced replication stress
within residual GSC populations following surgical
resection may be targeted with agents that exploit such
defective ATR signalling, for example. However, as is
unfortunately all too common in glioblastoma
research, promising preclinical studies do not necessar-
ily translate into clinical benefit for patients [3,214] so
expectations in this regard need to be measured.
4. Conclusions and future
perspectives
As highlighted in this Review, there is a critical need
for new and more effective treatment strategies to
combat the long-standing dismal survival rates experi-
enced by patients diagnosed with high-grade brain
tumours such as glioblastoma. Through the combined
acquisition of fundamental biological insights into
DDR mechanisms and interplay within this network
and associated pathways, together with continued pro-
gress in imaging, surgical technologies and
radiochemotherapy delivery within the clinic, it is
expected that targeting of the DDR has a potential to
tackle the historic lack of treatment options for these
tumours. It will be particularly interesting to see the
results of DDR inhibitor clinical trials currently in var-
ious phases around the world (Table 1), as this will
give an indication of how successful such approaches
may or may not be [145,215]. There is, of course, the
risk, given the extensive intratumoural heterogeneity of
glioblastoma and inherently treatment-resistant GSCs
within these tumours, that any single targeted therapy
may in fact be ‘too targeted’, leading to inevitable
resurgence of resistant subclones and tumour repopu-
lation. In a similar manner to other difficult-to-treat
diseases such as HIV and multidrug-resistant tubercu-
losis [216], novel drug combinations may be required
to overcome the extensive genetic heterogeneity and
resistance mechanisms observed in glioblastoma. Con-
sequently, as highlighted within this Review, targeting
multiple DDR constituents in parallel has the potential
to provide new effective treatment paradigms that
might help prevent disease progression by counteract-
ing complex and overarching phenotypic delinquency
within the DDR of cancerous cells (Fig. 3).
In addition to the aforementioned needed improve-
ment in preclinical models that better reflect postsurgi-
cal residual disease, an important factor alongside the
development of such multimodal strategies will be fur-
ther improvements in the efficient delivery of therapeu-
tically active doses of drugs beyond the BBB, which
remains a significant challenge in glioblastoma therapy
[3]. Potential innovations on the horizon include the
use of MRI-directed magnetic nanoparticles [217,218],
surgical delivery of in situ gelling agents [219,220] and
enhanced intrathecal/cerebrospinal fluid delivery using
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novel viral vectors, antibody ligands or exosomes
[221–223]. Such approaches, in addition to traditional
oral or intravenous delivery approaches, coupled with
novel ways to disrupt the BBB, such as ultrasound
[224,225] or TTFields [226]-based approaches, will
hopefully provide the best chance for DDR-targeting
approaches to provide much-needed clinical benefit to
patients and families faced with the devastating diag-
nosis of a high-grade glioma.
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